TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27342758
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered IGIV-C (200-600 mg/kg per infusion every 3-4 weeks)
Study: 27342758
Drug: Subcutaneously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administered IGIV-C (calculated using a conversion factor of 1.37 times the prior IV dose)
Study: 27342758
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered IGIV-C
Study: 27342758
Drug: Subcutaneously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administered IGIV-C
Study: 27345655
Drug: Intravesical BCG
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical BCG vaccine or intravesical chemotherapy for non-muscle-invasive bladder cancer
Study: 27345655
Drug: Radical cystectomy
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical cystectomy with neoadjuvant chemotherapy for muscle-invasive bladder cancer
Study: 27345655
Drug: Bladder-sparing trimodality
Normalized name: Sus scrofa urinary bladder preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder-sparing trimodality treatment consisting of transurethral resection with chemoradiation for selected patients with muscle-invasive tumours
Study: 27345655
Drug: Systemic cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic cisplatin-based chemotherapy for advanced disease
Study: 27345655
Drug: Immunotherapy as
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy as a salvage treatment for patients in whom first-line chemotherapy cannot control the disease
Study: 27347680
Drug: Cenicriviroc (CVC)
Normalized name: salicylic acid
DrugBank: Cenicriviroc (DB11758)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenicriviroc (CVC) at doses ≥20 mg/kg/day
Study: 27350064
Drug: LY2603618 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2603618 (150 mg/m², day 2) and pemetrexed (500 mg/m², day 1) every 21 days until disease progression
Study: 27350064
Drug: LY2603618 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2603618 and pemetrexed combination therapy
Study: 27350760
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg with clopidogrel 600 mg
Study: 27350760
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg alone
Study: 27351006
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/d for 6 months
Study: 27351341
Drug: Ledipasvir (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir (90 mg) plus Sofosbuvir (400 mg) once daily for 12 weeks
Study: 27352238
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 150mg once daily (qd)
Study: 27352735
Drug: Mifepristone 200mg
Normalized name: MIFEPRISTONE 200MG TAB UD
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone 200mg followed by misoprostol 600μg sublingual 24-48 hours later
Study: 27353267
Drug: TDF/FTC therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF/FTC therapy for at least 30 days
Study: 27354021
Drug: CD25/regulatory T-cell-depleted
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD25/regulatory T-cell-depleted donor lymphocyte infusion
Study: 27354476
Drug: Pembrolizumab, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab, 10 mg/kg every 2 weeks until disease progression
Study: 27354481
Drug: Nivolumab 10
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 10 mg/kg plus gemcitabine-cisplatin
Study: 27354481
Drug: Nivolumab 10
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 10 mg/kg plus pemetrexed-cisplatin
Study: 27354481
Drug: Nivolumab 10
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 10 mg/kg plus paclitaxel-carboplatin
Study: 27354481
Drug: Nivolumab 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 5 mg/kg plus paclitaxel-carboplatin
Study: 27354485
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg intravenously every 2 weeks until progression or unacceptable toxicity
Study: 27354719
Drug: Lenalidomide-bendamustine-rituximab (L-B-R)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide-bendamustine-rituximab (L-B-R)
Study: 27355323
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with Pegylated-interferon
Study: 27355323
Drug: Treatment (HCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (HCV n = 74, SVR 55%; HCV/HIV n = 37, SVR 74%)
Study: 27355533
Drug: Midostaurin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin (100 mg twice daily)
Study: 27356482
Drug: Chronic l-citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic l-citrulline supplementation
Study: 27356482
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no l-citrulline supplementation)
Study: 27356754
Drug: Traditional medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional medicine provided by traditional birth attendants
Study: 27356968
Drug: Community saving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community saving schemes for transport and medication
Study: 27357359
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy (specifics not provided)
Study: 27357695
Drug: Traditional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatments for seizures; herbs, concoctions, incisions, topical application of black soap
Study: 27357738
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (1.71 mg/kg for 3 days, then 2.14 mg/kg if no safety concerns)
Study: 27358088
Drug: 24-hour PWA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour PWA electronic health (e-health) solution
Study: 27358490
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (LdD, received 1,000 IU VitD daily)
Study: 27358490
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (HdD, received 5,000 IU VitD daily)
Study: 27362300
Drug: Robatumumab (19D12;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robatumumab (19D12; MK-7454; SCH717454) administered every 2 weeks
Study: 27363516
Drug: [2-(14)C](-)-epicatechin (300 μCi,
Approvals — FDA: no, EMA: no, PMDA: no
Description: [2-(14)C](-)-epicatechin (300 μCi, 60 mg)
Study: 27367154
Drug: Vorinostat 400
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 400 mg po qd for 28 days followed by a 7-day treatment-free period (5-week cycle)
Study: 27370649
Drug: Targeted fortification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted fortification of human milk (adding macronutrients to achieve 4.4 g fat, 8.8 g carbohydrates, and 3 g protein per 100 ml)
Study: 27371698
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg orally once daily, days 1-21 of a 28-day cycle
Study: 27373141
Drug: Liquid formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation of Rotarix™ (GlaxoSmithKline, Belgium)
Study: 27373141
Drug: Lyophilized formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized formulation of Rotarix™
Study: 27373595
Drug: Other DTaP-containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other DTaP-containing vaccines
Study: 27374464
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg/day plus R-CHOP-21 (intravenous rituximab 375 mg/m(2), intravenous cyclophosphamide 750 mg/m(2), intravenous doxorubicin 50 mg/m(2), intravenous vincristine 1·4 mg/m(2) [maximum 2·0 mg], oral prednisone 100 mg/m(2) on days 1-5 of the cycle) for six cycles.
Study: 27374464
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg/day plus R-CHOP-21
Study: 27374466
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of non-HLA-matched ex-vivo expanded cord blood progenitor cells after chemotherapy
Study: 27374466
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of non-HLA-matched ex-vivo expanded cord blood progenitor cells
Study: 27374829
Drug: Serum vitamin
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum vitamin D (25(OH)D) levels categorized as ≤20 ng/mL
Study: 27374829
Drug: Predictive model
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive model based on supplement intake, nutritional status, race, and estimated creatinine clearance (eCCr)
Study: 27378554
Drug: Aspirin dose
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin dose ≥300 mg
Study: 27379560
Drug: Bortezomib (BTZ)
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib (BTZ) 1.3 mg/m of body surface area
Study: 27379610
Drug: Paclitaxel-coated SeQuent
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-coated SeQuent Please drug-coated balloon (DCB)
Study: 27379610
Drug: Clopidogrel discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel discontinuation after 4 weeks
Study: 27835722
Drug: Adjunctive brexpiprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive brexpiprazole (target dose: 3 mg/d)
Study: 27379966
Drug: Digital Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital Medicine System (DMS) with ingestible sensor and wearable sensor
Study: 27381904
Drug: Pomalidomide 4
Normalized name: pomalidomide 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 4 mg with weekly dexamethasone 20 mg (cohort 3)
Study: 27386049
Drug: One weekly
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One weekly low-level laser therapy treatment for six weeks
Study: 27386758
Drug: Concurrent enrollment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent enrollment of patients from some European Union founding members.
Study: 27387422
Drug: Hygiene-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hygiene-based intervention for skin and soft-tissue infection prevention; details on dosage and duration not available.
Study: 27387446
Drug: Ertumaxomab (ertu)
Normalized name: Ertumaxomab
DrugBank: Ertumaxomab (DB18923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertumaxomab (ertu) administered intravenously in 2 cycles with ascending doses (10-500 μg) weekly for 28 days with a 21-day treatment-free interval.
Study: 27387922
Drug: Full set
Normalized name: Silhouette Infusion Full Set-43 inch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full set of three satiety hormones
Study: 27387922
Drug: Set of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Set of two satiety hormones
Study: 27387922
Drug: Set of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Set of one satiety hormone
Study: 27388458
Drug: Biomedical interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biomedical interventions on STI/HIV testing and treatment
Study: 27388474
Drug: High-fat, high-protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat, high-protein (HFHP) meals with adaptive model-predictive insulin bolus
Study: 27388474
Drug: Insulin dose
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin dose adjustments for HFHP meals
Study: 27388610
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy (CRT-D) in non-obese patients
Study: 27388610
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy (CRT-D) in obese patients
Study: 27389402
Drug: NGF-ECB implants
Normalized name: Ecballium elaterium fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGF-ECB implants
Study: 27390847
Drug: AVDCX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVDCX regimen (cisplatin 25-35 mg/m2, docetaxel 25-35 mg/m2, capecitabine 1,600 mg/m2, bevacizumab 7.5 mg/kg)
Study: 27390847
Drug: AVDCX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVDCX regimen at maximum tolerated dose (MTD)
Study: 27391902
Drug: Calcium-free fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-free fluid with magnesium concentration of 1.50 mmol/l
Study: 27391902
Drug: High magnesium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High magnesium containing fluid (3,000 ml/h)
Study: 27391902
Drug: Calcium-free fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-free fluid with magnesium concentration of 0.75 mmol/l
Study: 27392483
Drug: MK8245 (liver-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK8245 (liver-specific SCD-1 inhibitor)
Study: 27392483
Drug: Direct anti-viral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct anti-viral agents and interferon-alpha therapy
Study: 27396777
Drug: Implantable intravascular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable intravascular delivery system for treprostinil infusion
Study: 27398025
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate 1.4 mg/m(2) on days 1 and 8
Study: 27398025
Drug: Capecitabine 1250
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1250 mg/m(2) on days 1-14
Study: 27399982
Drug: Intravenous polyspecific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous polyspecific immunoglobulin G (IVIG)
Study: 27400222
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol 400 mg subcutaneously at weeks 0, 2, and 4, then every 4 weeks thereafter up to 360 weeks
Study: 27401360
Drug: Prokinetics, laxatives,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prokinetics, laxatives, and physiotherapy
Study: 27402060
Drug: Docetaxel as
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel as first subsequent therapy (FST)
Study: 27402060
Drug: No subsequent
Approvals — FDA: no, EMA: no, PMDA: no
Description: No subsequent therapy
Study: 27402093
Drug: GSK2647544, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2647544, administered at a twice-daily dose of 102 mg, at steady state.
Study: 27402170
Drug: Renin-angiotensin-aldosterone system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-angiotensin-aldosterone system blockers (including angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, dual therapy, and statins)
Study: 27402854
Drug: Drug-eluting stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stent implantation with intravascular ultrasound evaluation
Study: 27402854
Drug: Drug-eluting stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stent implantation with dissection
Study: 27403301
Drug: Saccharomyces cerevisiae
Normalized name: Saccharomyces cerevisiae
DrugBank: Saccharomyces cerevisiae (DB10447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces cerevisiae I-3856 (1000 mg per day)
Study: 27403301
Drug: Saccharomyces cerevisiae
Normalized name: Saccharomyces cerevisiae
DrugBank: Saccharomyces cerevisiae (DB10447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces cerevisiae I-3856 (1000 mg per day) in IBS-C subgroup
Study: 27404453
Drug: Nab-paclitaxel (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel (150 mg/m² every 2 weeks) in combination with cisplatin, capecitabine, and gemcitabine (PAXG regimen)
Study: 27404941
Drug: CEA TCB
Normalized name: CEA TCB
DrugBank: Cibisatamab (DB17349)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEA TCB (T-cell-bispecific monoclonal antibody)
Study: 27406645
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for 4 months
Study: 27406645
Drug: Post-CPAP therapy
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-CPAP therapy assessment
Study: 27406646
Drug: Optimal care
Normalized name: STANNOUS FLUORIDE 0.16 g in 100 g ORAL PASTE, DENTIFRICE [Equate Optimal Care TP Equate Optimal Care TP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal care (all eligible guideline-indicated treatments)
Study: 27406646
Drug: Acute aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute aspirin
Study: 27406646
Drug: Aspirin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin at discharge
Study: 27409470
Drug: Small incision
Normalized name: Seprafilm Small Incision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small incision lenticule extraction (SMILE) for treatment of myopia
Study: 27410906
Drug: 17β-estradiol treatment
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17β-estradiol treatment for 1.7 years (median duration) in 60 girls with CTS
Study: 27410923
Drug: Ipilimumab at
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab at a dose of 10 mg per kilogram every 3 weeks for a total of 4 doses, with additional doses every 12 weeks for up to 60 weeks in patients who had a clinical benefit.
Study: 27410923
Drug: Ipilimumab at
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab at a dose of 3 mg per kilogram every 3 weeks for a total of 4 doses.
Study: 27411053
Drug: Pre-specified oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-specified oral cancer associated genes (IL8, IL1, SAT, OAZ1, DUSP1, S100P)
Study: 27411451
Drug: Low elastance
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low elastance group (L group, n = 10)
Study: 27411452
Drug: Esmolol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol therapy
Study: 27411683
Drug: IV nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV nab-paclitaxel 260 mg/m² on day 1 plus IV cisplatin 75 mg/m² on day 1
Study: 27411683
Drug: IV nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV nab-paclitaxel 140 mg/m² on days 1 and 8 plus IV cisplatin 75 mg/m² on day 1
Study: 27411683
Drug: IV nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV nab-paclitaxel 100 mg/m² on days 1, 8, and 15 plus IV cisplatin 75 mg/m² on day 1
Study: 27411683
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (nab-paclitaxel plus cisplatin)
Study: 27412386
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg orally twice daily during chemoradiation, up to 1 week before surgery, and for 6 months following surgery; Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 weekly during chemoradiation with 5040 cGy radiation therapy
Study: 27412526
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium topical gel (1%), applied up to 4 times daily
Study: 27412883
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of 20 million allogeneic adipose-derived stem cells in the vaginal walls and fistula tract, followed by a second dose of 40 million if necessary.
Study: 27412889
Drug: CAR-BCMA T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-BCMA T cells (4th dose level: 9 × 10(6) CAR(+) T cells/kg body weight)
Study: 27412889
Drug: CAR-BCMA T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-BCMA T cells (lowest 2 dose levels)
Study: 27413040
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) for 12 months
Study: 27413040
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor)
Study: 27413127
Drug: Diet behavior
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet behavior modification treatment (D group)
Study: 27413577
Drug: Medication use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication use at discharge
Study: 27413577
Drug: Medication use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication use at month 6
Study: 27413577
Drug: Polypharmacy (number
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy (number of categories of treatments received)